Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection

Fürst, Daniel E.; Wallis, Robert S.; Broder, Michael S.; Beenhouwer, David O.

doi:10.1016/j.semarthrit.2006.02.001

Cited by 211 publications

(162 citation statements)

References 64 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…Localized IDO expression by cells within granulomas might be one of the mechanisms keeping T cells at bay. In patients with rheumatoid arthritis treated with TNF-α-neutralizing therapy using infliximab or etanercept (Enbrel), fulminant exacerbation of tuberculosis, listeriosis, and other granulomatous infections has recently been recognized as a severe adverse event (62)(63)(64)(65). Interestingly, in patients with Crohn disease, characterized by high local expression of IDO, treatment with infliximab led to reduced IDO expression (66).…”

Section: Discussionmentioning

confidence: 99%

Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection

Попов¹,

Abdullah²,

et al. 2006

View full text Add to dashboard Cite

Control of pathogens by formation of abscesses and granulomas is a major strategy of the innate immune system, especially when effector mechanisms of adaptive immunity are insufficient. We show in human listeriosis that DCs expressing indoleamine 2,3-dioxygenase (IDO), together with macrophages, are major cellular components of suppurative granulomas in vivo. Induction of IDO by DCs is a cell-autonomous response to Listeria monocytogenes infection and was also observed in other granulomatous infections with intracellular bacteria, such as Bartonella henselae. Reporting on our use of the clinically applied anti-TNF-α antibody infliximab, we further demonstrate in vitro that IDO induction is TNF-α dependent. Repression of IDO therefore might result in exacerbation of granulomatous diseases observed during anti-TNF-α therapy. These findings place IDO + DCs not only at the intersection of innate and adaptive immunity but also at the forefront of bacterial containment in granulomatous infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection

Попов¹,

Abdullah²,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Tuberculosis-Although pre-registration studies with anti-TNFα agents revealed 15 cases of TB among over 8000 treated RA patients, passive surveillance studies have suggested a higher incidence of TB in association with TNFα antagonists [88]. There have been several reviews of the FDA's AERS examining TB associated with TNFα antagonists.…”

Section: Adverse Consequences Of Tnfα Blockade Therapies Infectionsmentioning

confidence: 99%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

“…In this regard, while infliximab and adalimumab increase lysis of CD4 and CD8 cells, hence reducing Interferon-expression, etanercept increases production of Interferon-α, which is essential in granuloma formation [32]. On the contrary, other Authors underline that tuberculous granulomas are more frequent in patients treated with anti-TNFα monoclonal antibodies, but it can be observed also with etanercept [33]; so, other mechanisms could be implicated.…”

Section: Case Descriptionmentioning

confidence: 99%

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Cassone¹

2017

Clin Med Rev Case Rep

View full text Add to dashboard Cite

Tumor Necrosis Factor (TNF)-α blockers have been shown to be highly effective in the treatment of arthritis not responsive to traditional therapy. In parallel, there are an increasing number of reports about the development of cutaneous side effects after the administration of anti-TNF-α agents. Noninfectious cutaneous granulomatous reactions include granuloma annulare, non-caseating granuloma, sarcoid-like granulomatosis and also a wide spectrum of conditions recently unified under the term of reactive granulomatous dermatitis.The majority of the above reported granulomatous dermatitis is associated with an underlying inflammatory disorder, and almost all may be drug-induced. Moreover, a substantial overlap, both in clinical and histologic features, is present between these conditions. We describe a reactive granulomatous dermatitis in a patient with psoriatic arthritis treated with adalimumab, resolved after the TNF-α inhibitor discontinuation, and we summarize the recent case-reports in which reactive granulomatous dermatitis were observed in patients with arthritis receiving various TNF-α inhibitors. Reactive granulomatous dermatitis may be a possible long-term side effect of this class of drugs. Although TNF-α blockers are usually used in the treatment of granulomatous disorders, patients treated with these kinds of drugs should be carefully monitored as, in rare cases, TNF-α inhibitors may induce sufficient cytokine activation to support granuloma formation.

show abstract

Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection

Cited by 211 publications

References 64 publications

Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection

Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection

TNFα blockade in human diseases: An overview of efficacy and safety

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Contact Info

Product

Resources

About